Pathogenesis and treatment of Hodgkin's disease

被引:1
作者
Tesch, H [1 ]
Bohlen, H [1 ]
Wolf, J [1 ]
Engert, A [1 ]
机构
[1] Univ Cologne, Innere Med Klin 1, D-50924 Cologne, Germany
关键词
Hodgkin's disease; chemotherapy; pathogenesis; immunotherapy;
D O I
10.1007/BF03043282
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although the pathogenesis of Hodgkin's disease is not clear, molecular analyses reveal characteristic features. EBV infection can be demonstrated in more than 50% of cases at the DNA or protein level. Recently, immunoglobulin gene rearrangements were found in single Hodgkin and Reed-Stemberg cells. Sequence analyses revealed that the rearranged Ig genes have frequently somatic mutations, which indicate that the tells are derived from the germinal center. These rearrangements may be used as defined markers to detect residual disease after chemotherapy. Modern polychemotherapy regimen and radiotherapy are very effective, and 60-90% of patients, depending on stage of the disease and risk factors, can be cured. Salvage therapy for relapsed patients including high-dose chemotherapy with autologous stem cell support frequently results in remission although duration is frequently short. New immunotherapy strategies with immunotoxins or bispecific antibodies are currently analysed in clinical studies.
引用
收藏
页码:82 / 90
页数:11
相关论文
共 72 条
[1]   AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH RELAPSED HODGKINS-DISEASE [J].
ARMITAGE, JO ;
BIERMAN, PJ ;
VOSE, JM ;
ANDERSON, JR ;
WEISENBURGER, DD ;
KESSINGER, A ;
REED, EC ;
VAUGHAN, WP ;
COCCIA, PF ;
PURTILO, DT .
AMERICAN JOURNAL OF MEDICINE, 1991, 91 (06) :605-611
[2]   TREATMENT STRATEGIES FOR PATIENTS WITH RELAPSED OR REFRACTORY HODGKINS-DISEASE [J].
ARMITAGE, JO .
ANNALS OF ONCOLOGY, 1995, 6 (06) :517-518
[3]  
BIERMAN PJ, 1994, BLOOD, V83, P1161
[4]   HIGH-DOSE CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS HEMATOPOIETIC RESCUE IN HODGKINS-DISEASE - LONG-TERM FOLLOW-UP IN 128 PATIENTS [J].
BIERMAN, PJ ;
BAGIN, RG ;
JAGANNATH, S ;
VOSE, JM ;
SPITZER, G ;
KESSINGER, A ;
DICKE, KA ;
ARMITAGE, JO .
ANNALS OF ONCOLOGY, 1993, 4 (09) :767-773
[5]   ALTERNATING NON-CROSS-RESISTANT COMBINATION CHEMOTHERAPY OR MOPP IN STAGE-IV HODGKINS-DISEASE - A REPORT OF 8-YEAR RESULTS [J].
BONADONNA, G ;
VALAGUSSA, P ;
SANTORO, A .
ANNALS OF INTERNAL MEDICINE, 1986, 104 (06) :739-746
[6]   ABVD CHEMOTHERAPY IN THE TREATMENT OF HODGKINS-DISEASE [J].
BONADONNA, G ;
SANTORO, A .
CANCER TREATMENT REVIEWS, 1982, 9 (01) :21-35
[7]  
BONFANTE V, 1995, 3 INT S HODG LYMPH K
[8]   CHEMOTHERAPY OF ADVANCED HODGKINS-DISEASE WITH MOPP, ABVD, OR MOPP ALTERNATING WITH ABVD [J].
CANELLOS, GP ;
ANDERSON, JR ;
PROPERT, KJ ;
NISSEN, N ;
COOPER, MR ;
HENDERSON, ES ;
GREEN, MR ;
GOTTLIEB, A ;
PETERSON, BA .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (21) :1478-1484
[9]   HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN 50 ADVANCED RESISTANT HODGKINS-DISEASE PATIENTS - AN ITALIAN STUDY-GROUP REPORT [J].
CARELLA, AM ;
CONGIU, AM ;
GAOZZA, E ;
MAZZA, P ;
RICCI, P ;
VISANI, G ;
MELONI, G ;
CIMINO, G ;
MANGONI, L ;
COSER, P ;
CETTO, GL ;
CIMINO, R ;
ALESSANDRINO, EP ;
BRUSAMOLINO, E ;
SANTINI, G ;
TURA, S ;
MANDELLI, F ;
RIZZOLI, V ;
BERNASCONI, C ;
MARMONT, AM .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (09) :1411-1416
[10]   EPIDEMIOLOGIC PATTERNS OF HODGKINS DISEASE [J].
CORREA, P ;
OCONOR, GT .
INTERNATIONAL JOURNAL OF CANCER, 1971, 8 (02) :192-+